Skip to main content
Top
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Rectal Cancer | Research

Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis

Authors: Haohui Yu, Tao Huang, Bin Feng, Jun Lyu

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

We collected information on patients with rectal adenocarcinoma in the United States from the Surveillance, Epidemiology, and EndResults (SEER) database. We used this information to establish a model that combined deep learning with a multilayer neural network (the DeepSurv model) for predicting the survival rate of patients with rectal adenocarcinoma.

Methods

We collected patients with rectal adenocarcinoma in the United States and older than 20 yearswho had been added to the SEER database from 2004 to 2015. We divided these patients into training and test cohortsat a ratio of 7:3. The training cohort was used to develop a seven-layer neural network based on the analysis method established by Katzman and colleagues to construct a DeepSurv prediction model. We then used the C-index and calibration plots to evaluate the prediction performance of the DeepSurv model.

Results

The 49,275 patients with rectal adenocarcinoma included in the study were randomly divided into the training cohort (70%, n = 34,492) and the test cohort (30%, n = 14,783). There were no statistically significant differences in clinical characteristics between the two cohorts (p > 0.05). We applied Cox proportional-hazards regression to the data in the training cohort, which showed that age, sex, marital status, tumor grade, surgery status, and chemotherapy status were significant factors influencing survival (p < 0.05). Using the training cohort to construct the DeepSurv model resulted in a C-index of the model of 0.824, while using the test cohort to verify the DeepSurv model yielded a C-index of 0.821. Thesevalues show that the prediction effect of the DeepSurv model for the test-cohort patients was highly consistent with the prediction resultsfor the training-cohort patients.

Conclusion

The DeepSurv prediction model of the seven-layer neural network that we have established can accurately predict the survival rateand time of rectal adenocarcinoma patients.
Literature
1.
go back to reference Stijns RCH, de Graaf EJR, Punt CJA, et al. Long-term oncological and functional outcomes of Chemoradiotherapy followed by organ-sparing Transanal endoscopic microsurgery for distal rectal Cancer: the CARTS study. JAMA Surg. 2019;154(1):47–54.CrossRef Stijns RCH, de Graaf EJR, Punt CJA, et al. Long-term oncological and functional outcomes of Chemoradiotherapy followed by organ-sparing Transanal endoscopic microsurgery for distal rectal Cancer: the CARTS study. JAMA Surg. 2019;154(1):47–54.CrossRef
2.
go back to reference Mullaney TG, Lightner AL, Johnston M, et al. 'Watch and Wait' after Chemoradiotherapy for rectal Cancer. ANZ J Surg. 2018;88(9):836–41.CrossRef Mullaney TG, Lightner AL, Johnston M, et al. 'Watch and Wait' after Chemoradiotherapy for rectal Cancer. ANZ J Surg. 2018;88(9):836–41.CrossRef
3.
go back to reference Bray F, et al. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, et al. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
4.
go back to reference Kimberly D. Miller, Leticia Nogueira, Angela B Mariotto, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.CrossRef Kimberly D. Miller, Leticia Nogueira, Angela B Mariotto, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.CrossRef
5.
go back to reference Rebecca L. Siegel, Kimberly D miller, Ahmedin Jemal. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef Rebecca L. Siegel, Kimberly D miller, Ahmedin Jemal. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
6.
go back to reference Arnold D, Stein A. Personalized treatment of colorectal Cancer. Onkologie. 2012;35(1):42–8.CrossRef Arnold D, Stein A. Personalized treatment of colorectal Cancer. Onkologie. 2012;35(1):42–8.CrossRef
7.
go back to reference Guglielmo A, Staropoli N, Giancotti M, et al. Personalized medicine in colorectal Cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Eff Resour Alloc. 2018;16:2.CrossRef Guglielmo A, Staropoli N, Giancotti M, et al. Personalized medicine in colorectal Cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Eff Resour Alloc. 2018;16:2.CrossRef
8.
go back to reference Provenzale D, Gupta S, Ahnen DJ, et al. NCCN guidelines insights: colorectal Cancer screening, version 1.2018. J Natl Compr Cancer Netw. 2018;16(8):939–49.CrossRef Provenzale D, Gupta S, Ahnen DJ, et al. NCCN guidelines insights: colorectal Cancer screening, version 1.2018. J Natl Compr Cancer Netw. 2018;16(8):939–49.CrossRef
9.
go back to reference Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(7):874–901.CrossRef Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(7):874–901.CrossRef
10.
go back to reference Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal Cancer. Nat Rev Dis Primers. 2015;1:15065.CrossRef Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal Cancer. Nat Rev Dis Primers. 2015;1:15065.CrossRef
11.
go back to reference Julião GPS, Habr-Gama A, Vailati BB, et al. New strategies in rectal Cancer. Surg Clin North Am. 2017;97(3):587–604.CrossRef Julião GPS, Habr-Gama A, Vailati BB, et al. New strategies in rectal Cancer. Surg Clin North Am. 2017;97(3):587–604.CrossRef
12.
go back to reference Deng Y. Rectal Cancer in Asian vs. Western countries: why the variation in incidence? Curr Treat Options in Oncol. 2017;18(10):64.CrossRef Deng Y. Rectal Cancer in Asian vs. Western countries: why the variation in incidence? Curr Treat Options in Oncol. 2017;18(10):64.CrossRef
13.
go back to reference Lee D, Matsuda T, Yamashita K, et al. Significance of lateral pelvic lymph node size in predicting metastasis and prognosis in rectal Cancer. Anticancer Res. 2019;39(2):993–8.CrossRef Lee D, Matsuda T, Yamashita K, et al. Significance of lateral pelvic lymph node size in predicting metastasis and prognosis in rectal Cancer. Anticancer Res. 2019;39(2):993–8.CrossRef
14.
go back to reference Yoshikawa K, Shimada M, Higashijima J, et al. Ki-67 and Survivin as predictive factors for rectal Cancer treated with preoperative Chemoradiotherapy. Anticancer Res. 2018;38(3):1735–9.PubMed Yoshikawa K, Shimada M, Higashijima J, et al. Ki-67 and Survivin as predictive factors for rectal Cancer treated with preoperative Chemoradiotherapy. Anticancer Res. 2018;38(3):1735–9.PubMed
15.
go back to reference Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–52.CrossRef Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–52.CrossRef
16.
go back to reference Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–80.CrossRef Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–80.CrossRef
17.
go back to reference Capurso G, Gaujoux S, Pescatori LC, et al. The ENETS TNM stage and grading system accurately predict prognosis in patients with rectal NENs. Dig Liver Dis. 2019;51(12):1725–30.CrossRef Capurso G, Gaujoux S, Pescatori LC, et al. The ENETS TNM stage and grading system accurately predict prognosis in patients with rectal NENs. Dig Liver Dis. 2019;51(12):1725–30.CrossRef
18.
go back to reference Jiang Y, Xie J, Han Z, et al. Immunomarker support vector machine classifier for prediction of gastric Cancer survival and adjuvant chemotherapeutic benefit. Clin Cancer Res. 2018;24(22):5574–84.CrossRef Jiang Y, Xie J, Han Z, et al. Immunomarker support vector machine classifier for prediction of gastric Cancer survival and adjuvant chemotherapeutic benefit. Clin Cancer Res. 2018;24(22):5574–84.CrossRef
19.
go back to reference Kano S, Sakashita T, Tsushima N, et al. Validation of the 8th edition of the AJCC/UICC TNM stage system for tongue squamous cell carcinoma. Int J Clin Oncol. 2018;23(5):844–50.CrossRef Kano S, Sakashita T, Tsushima N, et al. Validation of the 8th edition of the AJCC/UICC TNM stage system for tongue squamous cell carcinoma. Int J Clin Oncol. 2018;23(5):844–50.CrossRef
20.
go back to reference Stijn van Roessel, Gyulnara G Kasumova, Joanne Verheij, et al. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM stage System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018;153(12):e183617. Stijn van Roessel, Gyulnara G Kasumova, Joanne Verheij, et al. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM stage System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018;153(12):e183617.
21.
go back to reference Walker R, Wood T, LeSouder E, et al. Comparison of two novel stage systems with the TNM system in predicting stage III Colon Cancer survival. J Surg Oncol. 2018;117(5):1049–57.CrossRef Walker R, Wood T, LeSouder E, et al. Comparison of two novel stage systems with the TNM system in predicting stage III Colon Cancer survival. J Surg Oncol. 2018;117(5):1049–57.CrossRef
22.
go back to reference Wang L-W, Lin H, Xin L, et al. Establishing a model to measure and predict the quality of gastrointestinal endoscopy. World J Gastroenterol. 2019;25(8):1024–30.CrossRef Wang L-W, Lin H, Xin L, et al. Establishing a model to measure and predict the quality of gastrointestinal endoscopy. World J Gastroenterol. 2019;25(8):1024–30.CrossRef
23.
go back to reference Churpek MM, Yuen TC, Winslow C, et al. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med. 2016;44(2):368–74.CrossRef Churpek MM, Yuen TC, Winslow C, et al. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med. 2016;44(2):368–74.CrossRef
24.
go back to reference Goerdten J, Carrière I, Muniz-Terrera G. Comparison of cox proportional hazards regression and generalized cox regression models applied in dementia risk prediction. Alzheimers Dement (N Y). 2020;6(1):e12041. Goerdten J, Carrière I, Muniz-Terrera G. Comparison of cox proportional hazards regression and generalized cox regression models applied in dementia risk prediction. Alzheimers Dement (N Y). 2020;6(1):e12041.
25.
go back to reference Asano J, Hirakawa A, Hamada C. Assessing the prediction accuracy of cure in the cox proportional hazards cure model: an application to breast Cancer data. Pharm Stat. 2014;13(6):357–63.CrossRef Asano J, Hirakawa A, Hamada C. Assessing the prediction accuracy of cure in the cox proportional hazards cure model: an application to breast Cancer data. Pharm Stat. 2014;13(6):357–63.CrossRef
26.
go back to reference Lor Randall R, Cable MG. Nominal nomograms and marginal margins: what is the law of the line? Lancet Oncol. 2016;17(5):554–6.CrossRef Lor Randall R, Cable MG. Nominal nomograms and marginal margins: what is the law of the line? Lancet Oncol. 2016;17(5):554–6.CrossRef
27.
go back to reference Woo Jung Kim, Ji Min Sung, David Sung, et al. Cox proportional Hazard regression versus a deep learning algorithm in the prediction of dementia: an analysis based on periodic health examination. JMIR med Inform. 2019;7(3):e13139. Woo Jung Kim, Ji Min Sung, David Sung, et al. Cox proportional Hazard regression versus a deep learning algorithm in the prediction of dementia: an analysis based on periodic health examination. JMIR med Inform. 2019;7(3):e13139.
28.
go back to reference Wainberg M, Merico D, Delong A, et al. Deep learning in biomedicine. Nat Biotechnol. 2018;36(9):829–38.CrossRef Wainberg M, Merico D, Delong A, et al. Deep learning in biomedicine. Nat Biotechnol. 2018;36(9):829–38.CrossRef
29.
go back to reference Levin DL. Deep learning and the evaluation of pulmonary fibrosis. Lancet. Respir Med. 2018;6(11):803–5. Levin DL. Deep learning and the evaluation of pulmonary fibrosis. Lancet. Respir Med. 2018;6(11):803–5.
30.
go back to reference Liu K, Xia W, Qiang M, et al. Deep learning pathological microscopic features in endemic nasopharyngeal Cancer: prognostic value and Protentional role for individual induction chemotherapy. Cancer Med. 2020;9(4):1298–306.CrossRef Liu K, Xia W, Qiang M, et al. Deep learning pathological microscopic features in endemic nasopharyngeal Cancer: prognostic value and Protentional role for individual induction chemotherapy. Cancer Med. 2020;9(4):1298–306.CrossRef
31.
go back to reference Katzman JL, Shaham U, Cloninger A, et al. DeepSurv: personalized treatment recommender system using a cox proportional hazards deep neural network. BMC Med Res Methodol. 2018;18(1):24.CrossRef Katzman JL, Shaham U, Cloninger A, et al. DeepSurv: personalized treatment recommender system using a cox proportional hazards deep neural network. BMC Med Res Methodol. 2018;18(1):24.CrossRef
32.
go back to reference Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomark Prev. 1999;8(12):1117–21. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomark Prev. 1999;8(12):1117–21.
33.
go back to reference Tan Y, Dongliang F, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant Chemoradiotherapy for rectal Cancer: a population-based analysis. Front Oncol. 2019;9:497.CrossRef Tan Y, Dongliang F, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant Chemoradiotherapy for rectal Cancer: a population-based analysis. Front Oncol. 2019;9:497.CrossRef
34.
go back to reference Bartos A, Bartos D, Stoian R, et al. Short-term outcome and survival after multiorgan resection for locally advanced Colo-rectal Cancer. Identification of risk factors. Ann Ital Chir. 2018;89:229–36.PubMed Bartos A, Bartos D, Stoian R, et al. Short-term outcome and survival after multiorgan resection for locally advanced Colo-rectal Cancer. Identification of risk factors. Ann Ital Chir. 2018;89:229–36.PubMed
35.
go back to reference Skrede O-J, De Raedt S, Kleppe A, et al. Deep learning for prediction of colorectal Cancer outcome: a discovery and validation study. Lancet. 2020;395(10221):350–60.CrossRef Skrede O-J, De Raedt S, Kleppe A, et al. Deep learning for prediction of colorectal Cancer outcome: a discovery and validation study. Lancet. 2020;395(10221):350–60.CrossRef
36.
go back to reference Motalleb G. Artificial neural network analysis in preclinical breast Cancer. Cell J Winter. 2014;15(4):324–31. Motalleb G. Artificial neural network analysis in preclinical breast Cancer. Cell J Winter. 2014;15(4):324–31.
37.
go back to reference Zhou J, Theesfeld CL, Yao K, et al. Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. Nat Genet. 2018;50(8):1171–9.CrossRef Zhou J, Theesfeld CL, Yao K, et al. Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. Nat Genet. 2018;50(8):1171–9.CrossRef
38.
go back to reference She Y, Jin Z, Junqi W, et al. Development and validation of a deep learning model for non-small cell lung Cancer survival. JAMA Netw Open. 2020;3(6):e205842.CrossRef She Y, Jin Z, Junqi W, et al. Development and validation of a deep learning model for non-small cell lung Cancer survival. JAMA Netw Open. 2020;3(6):e205842.CrossRef
39.
go back to reference Biglarian A, Bakhshi E, Gohari MR, et al. Artificial neural network for prediction of distant metastasis in colorectal Cancer. Asian Pac J Cancer Prev. 2012;13(3):927–30.CrossRef Biglarian A, Bakhshi E, Gohari MR, et al. Artificial neural network for prediction of distant metastasis in colorectal Cancer. Asian Pac J Cancer Prev. 2012;13(3):927–30.CrossRef
40.
go back to reference Rau H-H, Hsu C-Y, Lin Y-A, et al. Development of a web-based liver Cancer prediction model for type II diabetes patients by using an artificial neural network. Comput Methods Prog Biomed. 2016;125:58–65.CrossRef Rau H-H, Hsu C-Y, Lin Y-A, et al. Development of a web-based liver Cancer prediction model for type II diabetes patients by using an artificial neural network. Comput Methods Prog Biomed. 2016;125:58–65.CrossRef
41.
go back to reference Bibault J-E, Giraud P, Housset M, et al. Deep learning and Radiomics predict complete response after neo-adjuvant Chemoradiation for locally advanced rectal Cancer. Sci Rep. 2018;8(1):12611.CrossRef Bibault J-E, Giraud P, Housset M, et al. Deep learning and Radiomics predict complete response after neo-adjuvant Chemoradiation for locally advanced rectal Cancer. Sci Rep. 2018;8(1):12611.CrossRef
Metadata
Title
Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis
Authors
Haohui Yu
Tao Huang
Bin Feng
Jun Lyu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09217-9

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine